Table 4.
Receipt of cancer-directed surgery and radiation-therapy, by tumor site and race
| Cancer Site | Race/Ethnicity | Cancer-directed Surgery |
Radiotherapy |
||||
|---|---|---|---|---|---|---|---|
| Model-1 (n=13,234) | Model-2 (n=6,367) | Model-1 (n=13,234) | Model-2 (n=6,367) | ||||
| No. | OR(95% CI)* | No. | OR(95% CI) | OR(95% CI) | OR(95% CI) | ||
| All 8 cancers combined | |||||||
| NH-White | 10749 | 1.0(Ref)* | 5073 | 1.0(Ref) | 1.0(Ref) | 1.0(Ref) | |
| NH-Black | 922 | 0.7(0.6–0.8) | 409 | 0.5(0.4–0.6) | 1.0(0.8–1.2) | 1.1(0.9–1.5) | |
| NH-API | 678 | 1.1(0.9–1.4) | 372 | 1.2(0.9–1.7) | 1.1(0.9–1.4) | 1.2(0.9–1.6) | |
| Hispanic | 836 | 1.1(0.9–1.3) | 481 | 1.1(0.8–1.3) | 1.0(0.8–1.2) | 1.1(0.8–1.4) | |
| AI/AN | 49 | 0.9(0.4–1.9) | 32 | 0.9(0.4–2.2) | 0.8(0.3–1.7) | 0.8(0.3–2.1) | |
| Breast | |||||||
| NH-White | 2492 | 1.0(Ref) | 1169 | 1.0(Ref) | 1.0(Ref) | 1.0(Ref) | |
| NH-Black | 214 | 0.7(0.5–1.2) | 86 | 0.7(0.3–1.3) | 0.7(0.5–1.0) | 0.8(0.4–1.3) | |
| NH-API | 191 | 1.3(0.6–2.7) | 115 | 2.0(0.8–5.1) | 1.0(0.7–1.5) | 1.1(0.7–1.8) | |
| Hispanic | 216 | 0.9(0.5–1.5) | 129 | 1.5(0.8–2.7) | 1.2(0.9–1.7) | 1.2(0.8–2.0) | |
| Colorectal | |||||||
| NH-White | 1791 | 1.0(Ref) | 791 | 1.0(Ref) | 1.0(Ref) | 1.0(Ref) | |
| NH-Black | 140 | 0.7(0.5–1.1) | 56 | 0.5(0.3–1.0) | 0.9(0.5–1.5) | 0.6(0.2–1.5) | |
| NH-API | 145 | 1.0(0.6–1.7) | 75 | 1.2(0.6–2.3) | 1.1(0.6–2.1) | 1.3(0.6–3.4) | |
| Hispanic | 166 | 0.5(0.3–0.8) | 98 | 0.6(0.3–1.0) | 1.7(1.0–3.0) | 1.7(0.7–3.9) | |
| Prostate | |||||||
| NH-White | 2652 | 1.0(Ref) | 1232 | 1.0(Ref) | 1.0(Ref) | 1.0(Ref) | |
| NH-Black | 311 | 0.8(0.6–1.1) | 137 | 0.7(0.4–1.1) | 0.8(0.6–1.1) | 1.0(0.6–1.6) | |
| NH-API | 152 | 0.8(0.5–1.3) | 80 | 0.8(0.4–1.5) | 1.4(0.9–2.2) | 1.5(0.9–2.8) | |
| Hispanic | 252 | 1.3(0.9–1.9) | 132 | 0.9(0.5–1.5) | 0.7(0.5–1.0) | 1.1(0.7–1.8) | |
| Lung and bronchus | |||||||
| NH-White | 2241 | 1.0(Ref) | 1057 | 1.0(Ref) | 1.0(Ref) | 1.0(Ref) | |
| NH-Black | 207 | 0.8(0.5–1.3) | 101 | 0.5(0.2–1.1) | 1.0(0.7–1.3) | 1.4(0.8–2.2) | |
| NH-API | 126 | 2.0(1.1–3.6) | 69 | 1.8(0.8–4.0) | 0.9(0.6–1.5) | 1.0(0.6–1.9) | |
| Hispanic | 125 | 1.5(0.8–3.5) | 69 | 1.0(0.4–2.2) | 0.7(0.6–1.5) | 0.7(0.4–1.3) | |
| Ovarian | |||||||
| NH-White | 318 | 1.0(Ref) | 143 | 1.0(Ref) | 1.0(Ref) | 1.0(Ref) | |
| NH-Black | 29 | 0.9(0.3–2.4) | <20 | 0.6(0.1–2.8) | u/d | u/d | |
| NH-API | 17 | 5.3(0.8–35.0) | <20 | 5.1(0.4–72.4) | 10.6(1.3–87.1) | u/d | |
| Hispanic | 38 | 2.4(0.8–6.8) | 21 | 15.3(1.0–225) | 5.5(0.2–198.0) | 4.0(0.1–291.9) | |
| Urinary bladder | |||||||
| NH-White | 795 | 1.0(Ref) | 395 | 1.0(Ref) | 1.0(Ref) | 1.0(Ref) | |
| NH-Black | 29 | 0.5(0.2–1.3) | <20 | 0.7(0.1–4.2) | 0.5(0.1–2.1) | 1.6(0.3–10.2) | |
| NH-API | 38 | 2.0(0.8–5.2) | <20 | 2.2(0.5–9.1) | 0.30(0.1–1.3) | u/d | |
| Hispanic | 34 | 1.9(0.4–9.3) | 20 | 1.0(0.2–5.1) | 0.4(0.1–1.6) | 0.6(0.1–3.8) | |
‘Ref’ denotes ‘reference’. ‘u/d’ denotes ‘undefined’. ‘OR’ denotes ‘odds ratio’. To avoid any cell with N<16 (SEER data user agreement), cervical cancer and melanoma were not reported, AI/AN with cases <16 were not reported for other tumor sites, and <20 was reported for NH-Black and NH-API with ovarian and urinary bladder cancer.
*
Model-1: Hazard ratio (HR) adjusted for age, sex, tumor stage, education, poverty and family income.
Model-2: HR additionally adjusted for health insurance in subjects with data on health insurance.